PVI
Pura Vida Investments Portfolio holdings
AUM
$16.6M
This Quarter Return
+9.67%
1 Year Return
-3.82%
3 Year Return
-0.02%
5 Year Return
+29.84%
10 Year Return
+256.58%
AUM
$208M
AUM Growth
+$208M
(-28%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-49.54%
Top 10 Holdings %
Top 10 Hldgs %
45.39%
Holding
101
New
22
Increased
11
Reduced
15
Closed
35
Top Buys
| 1 |
ESRX
Express Scripts Holding Company
ESRX
|
$11.2M |
| 2 |
Labcorp
LH
|
$10M |
| 3 |
LivaNova
LIVN
|
$8.57M |
| 4 |
Merck
MRK
|
$8.33M |
| 5 |
ATHN
Athenahealth, Inc.
ATHN
|
$6.04M |
Top Sells
| 1 |
Hologic
HOLX
|
$10.7M |
| 2 |
BCR
CR Bard Inc.
BCR
|
$9.32M |
| 3 |
GSK
GSK
|
$8.25M |
| 4 |
Exact Sciences
EXAS
|
$7.96M |
| 5 |
UnitedHealth
UNH
|
$7.79M |
Sector Composition
| 1 | Healthcare | 80.06% |
| 2 | Industrials | 2.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EVHC
1
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $11.7M | 4.66% | 187,200 +47,200 | +34% | +$2.96M |
|
2
Boston Scientific
BSX
$156B
| $11.7M | 4.63% | 420,546 +55,546 | +15% | +$1.54M |
|
|
ESRX
3
DELISTED
Express Scripts Holding Company
ESRX
| $11.2M | 4.43% | +174,700 | New | +$11.2M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $10.7M | 4.26% | 88,112 +20,612 | +31% | +$2.51M |
|
|
5
Labcorp
LH
$23.1B
| $10M | 3.98% | +65,000 | New | +$10M |
|
|
6
LivaNova
LIVN
$3.08B
| $8.57M | 3.4% | +140,002 | New | +$8.57M |
|
|
7
Merck
MRK
$210B
| $8.33M | 3.31% | +130,000 | New | +$8.33M |
|
8
ICU Medical
ICUI
$3.15B
| $7.76M | 3.08% | 45,000 -5,000 | -10% | -$863K |
|
9
Baxter International
BAX
$12.7B
| $7.57M | 3% | 125,000 -55,000 | -31% | -$3.33M |
|
|
IVC
10
DELISTED
Invacare Corporation
IVC
| $6.67M | 2.65% | 505,000 -20,010 | -4% | -$264K |
|
11
Globus Medical
GMED
$8.27B
| $6.63M | 2.63% | 200,000 -85,646 | -30% | -$2.84M |
|
|
NSTG
12
DELISTED
NanoString Technologies, Inc.
NSTG
| $6.59M | 2.61% | 398,206 +255,456 | +179% | +$4.23M |
|
|
CLVS
13
DELISTED
Clovis Oncology, Inc.
CLVS
| $6.55M | 2.6% | 70,000 +38,750 | +124% | +$3.63M |
|
|
ATHN
14
DELISTED
Athenahealth, Inc.
ATHN
| $6.04M | 2.4% | +43,000 | New | +$6.04M |
|
|
NXTM
15
DELISTED
NxStage Medical Inc.
NXTM
| $5.56M | 2.21% | 221,685 -53,315 | -19% | -$1.34M |
|
|
XENT
16
DELISTED
Intersect ENT, Inc
XENT
| $5.52M | 2.19% | 197,498 -190,424 | -49% | -$5.32M |
|
|
PRAH
17
DELISTED
PRA Health Sciences, Inc.
PRAH
| $5.44M | 2.16% | +72,500 | New | +$5.44M |
|
|
QGENF
18
DELISTED
QIAGEN NV
QGENF
| $5.26M | 2.09% | 156,900 +4,400 | +3% | +$148K |
|
19
Bio-Rad Laboratories Class A
BIO
$8.06B
| $5.16M | 2.05% | 22,820 -30,180 | -57% | -$6.83M |
|
|
ABCO
20
DELISTED
Advisory Board Co/The
ABCO
| $5.15M | 2.04% | +100,000 | New | +$5.15M |
|
|
21
Exact Sciences
EXAS
$8.98B
| $4.42M | 1.76% | 125,000 -225,000 | -64% | -$7.96M |
|
22
Penumbra
PEN
$10.6B
| $4.39M | 1.74% | 50,000 -12,555 | -20% | -$1.1M |
|
|
TSRO
23
DELISTED
TESARO, Inc.
TSRO
| $4.18M | 1.66% | +29,900 | New | +$4.18M |
|
24
Gilead Sciences
GILD
$140B
| $3.54M | 1.41% | +50,000 | New | +$3.54M |
|
25
Supernus Pharmaceuticals
SUPN
$2.53B
| $3.45M | 1.37% | 80,000 -92,500 | -54% | -$3.99M |
|